重组人血小板生成素在中国治疗原发免疫性血小板减少症的预算影响分析

摘要

Objective: The study aimed to compare the impact of using Recombinant Human Thrombopoietin (rhTPO) versus without using rhTPO on insurance budget in the second-line treatment of Primary Immune Thrombocytopenia (ITP)in Chinese setting. Method: A one year Budget Impact model was constructed to estimate total direct medical cost with or without rhTPO in the second-line treatment of ITP. Result: The total average medical insurance expenses with or without rhTPO in one year in six cities (shanghai, Beijing, Guangzhou, Chengdu, Jinan, ad Wuhan) by urban employees medical insurance and urban/rural residents medical insurance are ¥ 482,900 and ¥ 151,900, respectively. Conclusion: When rhTPO is included in medical reimbursement drug list, it has small impact on medical insurance budget.%目的：从支付者角度比较使用和未使用重组人血小板生成素(rhTPO)作为二线治疗原发免疫性血小板减少症（ITP）方案对医保预算影响的差异，为临床提供有效且经济的治疗方案提供循证支持。方法：建立一个1年的预算影响模型（Budget Impact Model, BIM）用于比较重组人血小板生成素用于和未用于ITP的二线治疗的直接医疗费用。结果：将文献检索和专家问卷调查的数据输入预算影响模型，得到在研究的6个城市（上海、北京、广州、武汉、成都和济南）中，重组人血小板生成素用于与未用于ITP二线治疗，1年的城镇职工医保和城镇/城乡居民医保的费用预算影响的平均值分别为48.29万元和15.19万元。结论：重组人血小板生成素用于ITP二线治疗纳入医保后，对医保的冲击较小，在可承受范围。